Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Amgen: Phase 3 Results Highlight Novel Intravenous Calcimimetic Treatment Option

November 9, 2015 10:02 am | News | Comments

Amgen today presented the findings from a head-to-head Phase 3 study comparing intravenous etelcalcetide (AMG 416) with oral cinacalcet for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) receiving hemodialysis. Read more...


Amgen, Cytokinetics: COSMIC-HF Trial Data at AHA Scientific Sessions 2015

November 9, 2015 9:57 am | News | Comments

Amgen and Cytokinetics Incorporated today announced the presentation of data from the expansion phase of COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, in a Late-Breaking Clinical Trial session at the American Heart Association (AHA) Scientific Sessions 2015 in Orlando, Fla. Read more...


Two Drugs—FDA Approved for Arthritis and Blood Disorders—May Help Fight Baldness

November 9, 2015 9:14 am | by Cynthia Fox, Science Editor | Articles | Comments

Two oral drugs—approved by the FDA for inflammation in blood diseases (ruxolitinib) and rheumatoid arthritis (tofacitinib)—grow hair when slathered on skin, report surprised Columbia University researchers in Science Advances. Read more...


Is Allergy The Price We Pay for Our Immunity to Parasites?

November 9, 2015 8:15 am | by London School of Hygiene & Tropical Medicine | News | Comments

The findings support the hypothesis that allergic reactions are a flawed antibody response towards harmless environmental allergens. Read more...


Research Shows That Patients Fear Antidepressants a "Dirty Little Habit"

November 9, 2015 8:00 am | by Monash University | News | Comments

This research reveals that even before people take their first antidepressant, they are influenced by the controversial publicity surrounding the medication. Read more...


Potential Vaccine Aims to Block Transmission of Malaria Parasites

November 9, 2015 7:45 am | by University of Oxford | News | Comments

The vaccine candidate is composed of a transmission-blocking antigen from Plasmodium falciparum, the more dangerous form of malaria. Read more...

Gut Microbiota Regulates Antioxidant Metabolism

November 9, 2015 7:30 am | by Chalmers University of Technology | News | Comments

The functional output and diversity of gut microbiota are important modulators for the development of various human disorders. Read more...


Mucus - The First Line of Defense

November 9, 2015 7:15 am | by Lund University | News | Comments

The researchers also found that patients with two diseases that both cause mouth ulcers lack saliva that manages to stimulate a successful net formation. Read more...


AstraZeneca Acquires ZS Pharma in $2.7B Deal

November 9, 2015 7:00 am | by The Associated Press | News | Comments

The deal values the San Mateo, California-based company at $90 a share. Read more...


Cancer Treatment in a Painless Patch

November 6, 2015 10:58 am | by California Institute of Technology | News | Comments

Chemotherapy is a life-saving medical intervention for millions of cancer patients, but the treatment is often not a pleasant experience. To kill off cancer cells, chemotherapy drugs must directly enter the patient's bloodstream and so they are administered intravenously. But are large, often painful needles the only reliable way to deliver the drugs? Read more...


Less Than Half of U.S. Adults With Diabetes Understand Risk For Vision Loss: Survey

November 6, 2015 9:18 am | News | Comments

Regeneron Pharmaceuticals, Inc. announced that a new survey released today at the start of Diabetes Awareness Month found that less than half of recently surveyed U.S. adults with diabetes recognize their risk for vision loss. Read more...


Sanofi, Lexicon Pharmaceuticals to Collaborate on Oral Diabetes Medicine

November 6, 2015 9:13 am | News | Comments

Sanofi and Lexicon Pharmaceuticals, Inc. announced today that they have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes. Read more...


FDA Approves Gilead's New Four-in-One HIV Treatment

November 6, 2015 9:10 am | News | Comments

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1 infection. Read more...


Better Options for People with Treatment-Resistant Schizophrenia

November 6, 2015 9:04 am | by Columbia University | News | Comments

In real-world settings, patients with schizophrenia whose symptoms do not respond to standard antipsychotic medications have better outcomes if they are switched to clozapine instead of another standard antipsychotic. Read more...


SfN 2015 Recap: Harnessing the Power of Microglia in Neurodegenerative Diseases

November 6, 2015 8:49 am | by Stephanie Guzowski, Editor | Articles | Comments

Microglia, which comprise 10 to 15 percent of all cells found within the brain, act as the primary defenders in the central nervous system (CNS). But scientists are finding out that these immune cells play a significant role in shaping neural circuits, and may be implicated in developmental and neurodegenerative disorders. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.